Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by M.D. Anderson Cancer Center
Celgene Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: May 1, 2012
Last updated: August 7, 2015
Last verified: August 2015

The goal of this clinical research study is find the highest tolerable dose of romidepsin that can be given in combination with ifosfamide, carboplatin, etoposide (ICE) to patients with PTCL. The safety of this drug combination will also be studied.

Romidepsin is designed to stop the growth of cancer cells and block new blood vessels from forming around the cancer cells. This may cause the cancer cells to die.

Ifosfamide and etoposide are designed to slow or stop the growth of cancer cells.

Carboplatin is designed to interfere with the growth of cancer cells by stopping cell division, which may cause the cells to die.

Condition Intervention Phase
Drug: Romidepsin
Drug: Ifosfamide
Drug: Mesna
Drug: Carboplatin
Drug: Etoposide
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) of Romidepsin Plus ICE [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
    Maximum tolerated dose (MTD) is dose at which 20% of patients experience a dose limiting toxicity (DLT). DLT defined as drug-related adverse event with attribution of possible, probable, or definite and fulfilling one of following criteria. DLT assessment during cycle 1 of therapy. Adverse event grade 3 or 4 non-hematologic toxicity attributed to romidepsin that cannot be controlled or prevented by supportive care. Grade 4 thrombocytopenia or neutropenia that lasts for more than 14 days.

Estimated Enrollment: 30
Study Start Date: October 2012
Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Romidepsin + ICE

Starting dose of Romidepsin: 8 mg/m2 by vein on Days 1 and 4 of a 14 Day cycle.

Ifosfamide plus Mesna: 5 gm/m2 for both given by vein over 24 hours on Day 1 of a 14 Day cycle.

Mesna: 2 gm/m2 given by vein given over 12 hours on Day 1 of a 14 Day cycle. Starts after completion of Ifosfamide plus Mesna administration.

Carboplatin: mg to equal target area under curve (AUC) by Calvert equation of 5 mg/ml/min with a maximum of 750 mg, given by vein over 1 hour on Day 1 of a 14 Day cycle.

Etoposide: 100 mg/m2 given by vein over 2 hours on Days 1 - 3 of a 14 Day cycle.

Drug: Romidepsin
Starting Dose: 8 mg/m2 by vein on Days 1 and 4 of a 14 Day cycle.
Other Names:
  • Istodax
  • Depsipeptide
  • FK228
Drug: Ifosfamide
5 gm/m2 by vein on Day 1 of a 14 Day cycle.
Other Name: Ifex
Drug: Mesna

5 gm/m2 by vein given with Ifosfamide over 24 hours on Day 1 of a 14 Day cycle.

2 gm/m2 by vein given over 12 hours starting after completion of ifosfamide plus MESNA on Day 1 of a 14 Day cycle.

Other Name: Mesnex
Drug: Carboplatin
mg to equal target area under curve (AUC) by Calvert equation of 5 mg/ml/min with a maximum of 750 mg by vein on Day 1 of a 14 Day cycle.
Other Name: Paraplatin
Drug: Etoposide
100 mg/m2 by vein on Days 1 - 3 of a 14 Day cycle.
Other Name: VePesid

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Relapsed or refractory TCL status including diagnoses of peripheral TCL-NOS, angioimmunoblastic TCL, anaplastic large cell lymphoma, hepatosplenic TCL, enteropathy-associated TCL, or mycosis fungoides(MF)/cutaneous TCL with transformation to systemic TCL.
  2. Patients must have received at least one chemotherapy regimen which contained doxorubicin.
  3. At least one 1.5 cm bidimensional measurable lesion or bone marrow positivity of TCL.
  4. Eastern Cooperative Oncology Group (ECOG) performance status </= 2.
  5. Lab criteria of absolute neutrophil count (ANC) >/= 1000 cells/mm3, platelets >/= 80,000 cells/mm3 if baseline bone marrow negative for TCL involvement and platelets >/= 20,000 cells/mm3 if baseline bone marrow positive for TCL involvement, bilirubin </= 2 x upper limits of normal (ULN) (Gilbert's </= 3 x ULN), creatinine </= 1.5 x ULN, and ALT and AST </= 3 x ULN.
  6. Negative pregnancy test for females of childbearing potential within 7 days prior to start of treatment. Patients of reproductive potential must follow accepted birth control methods which include hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence during treatment and for 3 months after completion of treatment.
  7. Age of >/= 18 years.
  8. Voluntarily signed Institutional Review Board (IRB) approved informed consent document (ICD) before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria:

  1. History of another malignancy not in remission for at least 2 yrs (except non-melanoma skin cancer, stage 0 melanoma, localized prostate cancer, cervical cancer in situ)
  2. Known active Central Nervous System (CNS) lymphoma.
  3. Ejection fraction (EF) of < 40%, myocardial infarction (MI) within past 3 months, uncontrolled angina, severe uncontrolled ventricular arrythmias, or ECG evidence of acute ischemia.
  4. Grade 3 infection within 2 weeks of first dose romidepsin plus ICE.
  5. Pregnant or lactating.
  6. Receipt of another investigational drug within 14 days of enrollment.
  7. Patients with previous hypersensitivity reactions to the study drugs and components (ex: podophyllum and povidone).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01590732

Contact: Michelle A. Fanale, MD 713-792-2806

United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Celgene Corporation
Principal Investigator: Michelle A. Fanale, MD M.D. Anderson Cancer Center
  More Information

Additional Information:
No publications provided

Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01590732     History of Changes
Other Study ID Numbers: 2012-0183  NCI-2012-00847 
Study First Received: May 1, 2012
Last Updated: August 7, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:
Peripheral T-Cell Lymphoma
Relapsed or refractory T-Cell Lymphoma
Peripheral TCL-NOS
Angioimmunoblastic TCL
Anaplastic large cell lymphoma
Hepatosplenic TCL
Enteropathy-associated TCL

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Isophosphamide mustard
Alkylating Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on February 07, 2016